Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Choreo LLC

Choreo LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 47,354 shares of the biopharmaceutical company's stock after selling 7,178 shares during the period. Choreo LLC's holdings in Gilead Sciences were worth $5,306,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Redwood Financial Network Corp lifted its holdings in shares of Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock worth $234,000 after acquiring an additional 98 shares during the period. Argentarii LLC increased its position in shares of Gilead Sciences by 3.0% during the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock worth $380,000 after buying an additional 99 shares during the period. Nicolet Advisory Services LLC increased its position in shares of Gilead Sciences by 2.9% during the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after buying an additional 100 shares during the period. Peak Financial Advisors LLC grew its holdings in Gilead Sciences by 1.7% in the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock worth $677,000 after purchasing an additional 100 shares during the period. Finally, Perkins Coie Trust Co lifted its stake in shares of Gilead Sciences by 2.6% in the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after buying an additional 100 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider directly owned 121,152 shares of the company's stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,000 shares of company stock valued at $7,844,775. Company insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on GILD shares. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Finally, Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $111.38.

Gilead Sciences Price Performance

GILD stock opened at $110.17 on Wednesday. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The firm has a market capitalization of $137.04 billion, a P/E ratio of 23.19, a P/E/G ratio of 0.70 and a beta of 0.29. The business's 50-day moving average is $108.81 and its two-hundred day moving average is $105.35. Gilead Sciences, Inc. has a 1 year low of $70.78 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the company posted ($1.32) earnings per share. The firm's revenue was down .3% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.